If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 562.00
Bid: 560.00
Ask: 568.00
Change: 12.00 (2.18%)
Spread: 8.00 (1.429%)
Open: 560.00
High: 562.00
Low: 550.00
Prev. Close: 550.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Divestment of EM4

18 Mar 2024 14:36

RNS Number : 2868H
Gooch & Housego PLC
18 March 2024
 

 

18 March 2024

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

Divestment of EM4

 

Completion of an important milestone on the rationalisation of the Group's A&D product portfolio

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components and systems announces that it has sold its subsidiary EM4, LLC to EMFOUR Acquisition Co., LLC, a subsidiary of a US-based global technology company (the "Buyer") for a total consideration of up to $12.0m (£9.4m) (the "Disposal").

 

The EM4 business, located near Boston (MA), manufactures optoelectronic components and laser modules primarily for the US A&D market. The business also manufactured and supplied fused fibre couplers, but this product line has been excluded from the sale and transferred to the Group's Torquay facility.

 

The total consideration payable of up to $12.0m comprises an initial consideration of $5.25m (£4.1m) and deferred consideration of up to $6.75m (£5.3m). The initial consideration will be settled in cash subject to customary adjustments for working capital, cash and debt at completion. The deferred consideration, which is based upon the performance of the EM4 business in the period ending 30 September 2025, will be settled in cash. The net proceeds of the Disposal will be used to reduce the Group's borrowings.

 

In the Group's results for the year ended 30 September 2023, the elements of the EM4 business that are subject to the sale contributed £13.4m of revenue and delivered a loss before tax of £0.7m. Some of the Group's global function resources previously charged to the EM4 business will be redeployed following the Disposal to support the execution of the Group's strategy. At 31 January 2024, the book value of the gross assets of the business totalled £12.4m. The Disposal and its associated costs are expected to generate a non-underlying charge of circa £8.0m (cash effect circa £1.5m). The transaction is expected to be marginally accretive to underlying earnings for the year ending 30 September 2024.

Charlie Peppiatt, Chief Executive Officer of Gooch and Housego, commented:

"I am pleased to be able to report the completion of an important milestone on our journey to deliver sustainable margin growth for the Group. The divestment of EM4 is the result of a carefully considered and ongoing review of our A&D product portfolio."

"The Disposal supports the Group's consolidation of our A&D activities into areas where we can offer differentiated products to our customers and enable the Group to grow our optical systems business and maximise value creation from accretive optical systems solutions."

"I would like to thank the EM4 team in Boston for their contribution to G&H and wish them well for the future."

 

 

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / Sophie Wills / Abigail Gilchrist

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBSGDXSXBDGSI
Date   Source Headline
1st Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Jun 20202:53 pmRNSDirector/PDMR Shareholding
2nd Jun 202011:37 amRNSDirector/PDMR Shareholding
2nd Jun 20207:00 amRNSInterim Results
18th May 20207:00 amRNSNotification of Half Year Results
11th May 20207:00 amRNSAppointment of Non-Executive Director
23rd Apr 20204:23 pmRNSHolding(s) in Company
9th Apr 20203:25 pmRNSHolding(s) in Company
7th Apr 20207:00 amRNSHalf Year Trading Update
27th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20204:42 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSUS Facilities Update
17th Mar 20201:22 pmRNSFremont Facility Update
16th Mar 20201:56 pmRNSDirector/PDMR Shareholding
6th Mar 20209:45 amRNSDirector Share Purchase
3rd Mar 20207:00 amRNSStreamlining of Manufacturing
19th Feb 202012:23 pmRNSResult of AGM
19th Feb 20207:00 amRNSAGM Trading Update
3rd Feb 202012:08 pmRNSIssue of Equity and Total Voting Rights
14th Jan 202010:21 amRNSGrant of LTIP Awards
27th Dec 20193:26 pmRNSDirectorate: David Bauernfeind
11th Dec 20197:00 amRNSPosting of Annual Report and AGM Notice
9th Dec 20198:50 amRNSHolding(s) in Company
3rd Dec 20197:00 amRNSPreliminary Results
20th Nov 20198:42 amRNSBlock listing Interim Review
15th Nov 20194:41 pmRNSSecond Price Monitoring Extn
15th Nov 20194:35 pmRNSPrice Monitoring Extension
11th Nov 201911:18 amRNSConfirmation of Directorate Change
8th Nov 201912:54 pmRNSTotal Voting Rights
7th Oct 20197:00 amRNSFull Year Trading Update and Results Notification
6th Aug 201912:02 pmRNSPrice Monitoring Extension
18th Jul 201910:11 amRNSChief Financial Officer Appointment Timing Update
1st Jul 201910:57 amRNSDirector/PDMR Shareholding
6th Jun 201912:58 pmRNSDirector Share Purchase
4th Jun 20194:23 pmRNSDirectors' Share Purchases
4th Jun 20197:00 amRNSDirectorate Change
4th Jun 20197:00 amRNSInterim Results
28th May 20199:52 amRNSHolding(s) in Company
9th May 20197:00 amRNSNotification of Half Year Results
30th Apr 20197:00 amRNSAppointment of Chief Financial Officer
9th Apr 20197:00 amRNSCapital Markets Day
9th Apr 20197:00 amRNSHalf Year Trading Update
28th Mar 20195:28 pmRNSDirector/PDMR Shareholding
28th Mar 20195:25 pmRNSDirector/PDMR Shareholding
28th Mar 20195:24 pmRNSDirector/PDMR Shareholding
25th Mar 20195:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSITL signs manufacturing agreement with OrganOx
25th Feb 201911:27 amRNSDirector Share Purchase
21st Feb 20192:58 pmRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.